These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 16736510)

  • 1. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
    Parker AS; Kosari F; Lohse CM; Houston Thompson R; Kwon ED; Murphy L; Riehle DL; Blute ML; Leibovich BC; Vasmatzis G; Cheville JC
    Cancer; 2006 Jul; 107(1):37-45. PubMed ID: 16736510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma.
    Krambeck AE; Dong H; Thompson RH; Kuntz SM; Lohse CM; Leibovich BC; Blute ML; Sebo TJ; Cheville JC; Parker AS; Kwon ED
    Clin Cancer Res; 2007 Mar; 13(6):1749-56. PubMed ID: 17363528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
    Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
    J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other.
    Tollefson MK; Thompson RH; Sheinin Y; Lohse CM; Cheville JC; Leibovich BC; Kwon ED
    Cancer; 2007 Aug; 110(4):783-90. PubMed ID: 17594714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival.
    Parker AS; Cheville JC; Blute ML; Igel T; Lohse CM; Cerhan JR
    Cancer; 2004 Jun; 100(12):2577-82. PubMed ID: 15197799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome.
    Byun SS; Yeo WG; Lee SE; Lee E
    Urology; 2007 Jan; 69(1):34-7. PubMed ID: 17270609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.
    Ficarra V; Martignoni G; Lohse C; Novara G; Pea M; Cavalleri S; Artibani W
    J Urol; 2006 Apr; 175(4):1235-9. PubMed ID: 16515968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.
    Sengupta S; Lohse CM; Leibovich BC; Frank I; Thompson RH; Webster WS; Zincke H; Blute ML; Cheville JC; Kwon ED
    Cancer; 2005 Aug; 104(3):511-20. PubMed ID: 15973740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma.
    Haferkamp A; Bedke J; Vetter C; Pritsch M; Wagener N; Buse S; Crnkovic-Mertens I; Hoppe-Seyler K; Macher-Goeppinger S; Hoppe-Seyler F; Autschbach F; Hohenfellner M
    BJU Int; 2008 Dec; 102(11):1700-6. PubMed ID: 18990137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
    Thompson RH; Gillett MD; Cheville JC; Lohse CM; Dong H; Webster WS; Chen L; Zincke H; Blute ML; Leibovich BC; Kwon ED
    Cancer; 2005 Nov; 104(10):2084-91. PubMed ID: 16208700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
    Thompson RH; Kuntz SM; Leibovich BC; Dong H; Lohse CM; Webster WS; Sengupta S; Frank I; Parker AS; Zincke H; Blute ML; Sebo TJ; Cheville JC; Kwon ED
    Cancer Res; 2006 Apr; 66(7):3381-5. PubMed ID: 16585157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
    Yoo C; Song C; Hong JH; Kim CS; Ahn H
    J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.
    Shvarts O; Seligson D; Lam J; Shi T; Horvath S; Figlin R; Belldegrun A; Pantuck AJ
    J Urol; 2005 Mar; 173(3):725-8. PubMed ID: 15711252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Blute ML; Cheville JC; Lohse CM; Frank I; Kwon ED; Weaver AL; Parker AS; Zincke H
    Cancer; 2003 Apr; 97(7):1663-71. PubMed ID: 12655523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness.
    Kosari F; Parker AS; Kube DM; Lohse CM; Leibovich BC; Blute ML; Cheville JC; Vasmatzis G
    Clin Cancer Res; 2005 Jul; 11(14):5128-39. PubMed ID: 16033827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
    Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
    J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.